AYTU BIOSCIENCE, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOSCIENCE, INC. (Delaware) on January 27, 2016, covering events occurring on January 26, 2016. The registrant is a biopharmaceutical company headquartered in Englewood, Colorado.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
Effective January 26, 2016, the Board of Directors appointed two new directors:
- Joshua R. Disbrow: Previously employed by the company since April 2015. Former CEO of Luoxis Diagnostics, Inc. and COO of Ampio Pharmaceuticals, Inc.
- Jarrett Disbrow: Previously employed by the company since April 2015. Former CEO of Vyrix Pharmaceuticals, Inc. and founder/CEO of Arbor Pharmaceuticals, Inc.
Both directors will hold office until the next annual meeting of stockholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the appointment of the new directors.
Investor Verification Checklist
- Verify the biographies and prior roles of Joshua R. Disbrow and Jarrett Disbrow as disclosed in the filing.
- Confirm the effective date of the board appointments (January 26, 2016).
- Review the attached press release (Exhibit 99.1) for additional context on the appointments.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.